- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04281108
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) (FLUTE-2)
Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 With an Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis
This is a 2-part randomized, double-blind, placebo-controlled study followed by an open-label extension (OLE) of APT-1011 in adults with EoE.
Part A will evaluate the efficacy and safety of APT-1011 3 mg administered hora somni (HS; at bedtime) for the induction of response to treatment (histologic and symptomatic) over 12 weeks.
Part B will evaluate histological relapse-free status in patients re-randomized to continue APT-1011 or placebo (active treatment withdrawal) until Week 52.
Part C, the OLE, will continue until regulatory approval of APT-1011 or Sponsor termination of the study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 2-part randomized, double-blind, placebo-controlled study followed by an OLE of APT-1011 in adults with EoE.
Part A will evaluate the efficacy and safety of APT-1011 3 mg administered HS for the induction of response to treatment (histologic and symptomatic) over 12 weeks.
At Week 14, subjects will move into Part B. Subjects with histological response to APT-1011, defined as ≤6 peak eos/HPF, will be re-randomized to continue APT-1011 or receive placebo (active treatment withdrawal). APT-1011 histological non-responders will continue APT-1011, and placebo histological non-responders will receive APT-1011 3 mg HS. Placebo histological responders will continue placebo. The double-blind will be sustained throughout Part B. Histological responder status will be determined at the time of esophagogastroduodenoscopy (EGD) in Part B (at or prior to Week 52, depending on unscheduled EGDs performed when the Investigator deems the subject's symptoms necessitate EGD) and is defined as ≤6 peak eos/HPF.
At Week 52, subjects may enter Part C, an open-label single-arm extension phase, and continue study drug uninterrupted. Part C will terminate upon regulatory approval of APT-1011 or Sponsor termination of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- St. Vincent's Hospital Sydney
-
Kogarah, New South Wales, Australia, 2217
- Swallow Clinic, St George Hospital
-
New Lambton, New South Wales, Australia, 2305
- John Hunter Hospital
-
-
South Australia
-
Elizabeth Vale, South Australia, Australia, 5112
- Lyell McEwin Hospital
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- St. Vincent's Hospital
-
Melbourne, Victoria, Australia, 3004
- Alfred Hospital
-
-
-
-
-
Madrid, Spain, 28034
- Hospital Universitario Ramón y Cajal (Madrid)
-
-
Ciudad Real
-
Tomelloso, Ciudad Real, Spain, 13700
- Hosital General de Tomelloso
-
-
-
-
Alabama
-
Anniston, Alabama, United States, 36207
- Pinnacle Research Group, LLC
-
Dothan, Alabama, United States, 36305
- Gut P.C., dba; Digestive Health Specialists of the Southeast
-
Mobile, Alabama, United States, 36606
- East View Medical Research, LLC
-
-
Arizona
-
Tucson, Arizona, United States, 85712
- Del Sol Research Management, LLC
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- Preferred Research Partners Inc.
-
North Little Rock, Arkansas, United States, 72117
- Arkansas Gastroenterology
-
-
California
-
Camarillo, California, United States, 93012
- Camarillo Endoscopy Center
-
Canoga Park, California, United States, 91303
- Hope Clinical Research
-
Mission Hills, California, United States, 91345
- Facey Medical Foundation
-
Murrieta, California, United States, 92563
- United Medical Doctors
-
San Diego, California, United States, 92123
- Medical Associates Research Group
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80907
- Asthma and Allergy Associates, PC
-
Colorado Springs, Colorado, United States, 80907
- Peak Gastroenterology Associates
-
Wheat Ridge, Colorado, United States, 80033
- Western States Clinical Research Inc.
-
-
Connecticut
-
Danbury, Connecticut, United States, 06810
- Western Connecticut Medical Group - Gastroenterology
-
Hamden, Connecticut, United States, 06518
- Medical Research Center of Connecticut, LLC
-
-
Florida
-
Fleming Island, Florida, United States, 32003
- Fleming Island Center for Clinical Research
-
Inverness, Florida, United States, 34452
- Nature Coast Clinical Research
-
Jacksonville, Florida, United States, 32256
- ENCORE Borland Groover Clinical Research
-
Orlando, Florida, United States, 32803
- Endoscopic Research, Inc.
-
Pembroke Pines, Florida, United States, 33029
- DBC Research USA
-
-
Georgia
-
Athens, Georgia, United States, 30607
- Summit Clinical Research
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Maryland
-
Chevy Chase, Maryland, United States, 20815
- MGG Group Co., Inc., Chevy Chase Clinical Research
-
Columbia, Maryland, United States, 21045
- Gastro Center of Maryland
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Michigan Medicine, University of Michigan
-
Chesterfield, Michigan, United States, 48047
- Clinical Research Institute of Michigan LLC
-
Novi, Michigan, United States, 48377
- Henry Ford Health System
-
Wyoming, Michigan, United States, 49519
- West Michigan Clinical Research Center
-
-
Minnesota
-
Plymouth, Minnesota, United States, 55446
- Minnesota Gastroenterology, P.A.
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Chesterfield, Missouri, United States, 63005
- Clinical Research Professionals
-
-
Montana
-
Bozeman, Montana, United States, 59715
- Bozeman Health GI Clinic
-
-
New York
-
Great Neck, New York, United States, 11023
- Long Island Gastrointestinal Research Group LLP
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina Health Systems (UNC Hospital)
-
Greenville, North Carolina, United States, 27834
- Carolina Research
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Consultants for Clinical Research
-
Cincinnati, Ohio, United States, 45231
- Bernstein Clinical Research Center, LLC
-
Mentor, Ohio, United States, 44060
- Great Lakes Gastroenterology Research, LLC
-
Westlake, Ohio, United States, 44145
- Northshore Gastroenterology Research, LLC
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136
- Vital Prospects Clinical Research Institute, P.C.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Perelman Center for Advanced Medicine
-
Wyomissing, Pennsylvania, United States, 19610
- Digestive Disease Associates LTD
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Rapid City Medical Center LLP
-
-
Texas
-
Garland, Texas, United States, 75044
- DHAT Research Institute
-
-
Utah
-
Ogden, Utah, United States, 84405
- Advanced Research Institute
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Verity Research, Inc.
-
Lynchburg, Virginia, United States, 24502
- Blue Ridge Medical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female ≥18 years of age at the time of informed consent or assent
- Each subject must read, understand, and provide consent on the ICF for this study and be willing and able to adhere to study-related treatment regimens, procedures, and visit schedule
Diagnosis or presumptive diagnosis of EoE that is confirmed during the Screening period by histology that demonstrates ≥15 peak eos/HPF. In order to ensure that a diagnosis can be made, at least 6 biopsies should be taken including both proximal and distal specimens (at least 3 each). Mid-esophageal biopsies are not required (optional). HPF will be defined as a standard area of 235 square microns in a microscope with 40x lens (0.3 mm^2) and 22 mm ocular.
- Esophagogastroduodenoscopies and biopsies are to be obtained during the Screening period
- Biopsies will be read by a central pathologist
- Esophagogastroduodenoscopies and biopsies performed outside the study will not be accepted to meet eligibility criteria
- Optional biopsies may be taken and processed locally for local use, if specified in the local ICF. If serious pathology is unexpectedly encountered biopsies of such lesions must be processed locally
- Have a subject-reported history of ≥6 episodes of dysphagia in the 14 days prior to baseline
- Completion of the daily diary on at least 11 out of the 14 days during the 2-week Baseline Symptom Assessment
Exclusion Criteria:
- Have known contraindication, hypersensitivity, or intolerance to corticosteroids
- Have a contraindication to, or factors that substantially increase the risk of, EGD procedure or esophageal biopsy or have narrowing of the esophagus that precludes EGD with a standard 9 mm endoscope
- Have history of an esophageal stricture requiring dilatation within the 12 weeks prior to Screening
- Have any physical, mental, or social condition or history of illness or laboratory abnormality that in the Investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study or increase the safety risk to the subject such as uncontrolled diabetes or hypertension
- History or presence of oral or esophageal mucosal infection whilst using inhaled or nasal corticosteroids
- Have any mouth or dental condition that prevents normal eating (excluding braces)
- Have any condition affecting the esophageal mucosa or altering esophageal motility other than EoE, including erosive esophagitis (grade B or higher as per the Los Angeles Classification of Gastroesophageal Reflux Disease; hiatus hernia longer than 3 cm, Barrett's esophagus, and achalasia)
- Use of systemic (oral or parenteral) corticosteroids within 60 days before Screening, use of swallowed corticosteroids within 30 days before Screening
- Initiation of either inhaled or nasal corticosteroids or high-potency dermal topical corticosteroids within 30 days before Screening
- Use of calcineurin inhibitors or purine analogues (azathioprine, 6-mercaptopurine) in the 12 weeks before Screening
- Use of potent cytochrome P450 (CYP) 3A4 inhibitors (eg, ritonavir and ketoconazole) in the 12 weeks before Screening
- Initiation of an elimination diet or elemental diet within 30 days before Screening (diet must remain stable after signing ICF)
- Morning (07:00 to 09:00, or as close to that window as possible) serum cortisol level ≤5 μg/dL (138 nmol/L) that is not responsive to adrenocorticotropic hormone (ACTH) stimulation: defined as a serum cortisol level <16 μg/dL (440 nmol/L) at 60 minutes with ACTH stimulation test using 250 μg cosyntropin (i.e., an abnormal result on the ACTH stimulation test)
- Use of biologic immunomodulators in the 24 weeks before Screening (allergy desensitization injection or oral therapy is allowed as long as the course of therapy is not altered during the study period)
- Subjects who have initiated, discontinued, or changed dosage regimen of histamine H2 receptor antagonists, antacids or antihistamines for any condition such as gastro-esophageal reflux disease within 4 weeks before qualifying endoscopy during Screening. If already receiving these drugs, the dosage must remain constant throughout the study
- Subjects who have changed dosage regimen of PPIs within 8 weeks before qualifying endoscopy. If already receiving PPIs, the dosage must remain constant throughout the study
- Infection with hepatitis B, hepatitis C, or human immunodeficiency virus
- Have gastrointestinal bleeding or documented active peptic ulcer within 4 weeks prior to Screening or entering a new study period
- Have chronic infection such as prior or active tuberculosis, active chicken pox or measles or absence of prior measles, mumps and rubella vaccine. Subjects with tuberculosis exposure or who live in, or travel to, high endemic areas should be assessed locally for tuberculosis before consideration for the study
- Immunosuppression or immunodeficiency disorder
- Have a history or presence of Crohn's disease, celiac disease, or other inflammatory disease of the gastrointestinal tract, including eosinophilic gastroenteritis
- Have current drug abuse in the opinion of the Investigator.
- Have current alcohol abuse in the opinion of the Investigator.
- Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study
- Sexually active females of childbearing potential who do not agree to follow highly effective contraceptive methods through the End of Study visit
- Have received an investigational product, as part of a clinical trial within 30 days (or 5 half-lives, whichever is longest) of Screening. Subjects who are currently participating in observational studies or enrolled in patient registries are allowed in this study
- Have participated in a prior study with investigational product APT-1011
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: APT-1011
APT-1011 3 mg HS
|
APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
Other Names:
Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
|
Placebo Comparator: Placebo
HS
|
Placebo orally disintegrating tablet.
Other Names:
Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Week 12 histologic responder rates
Time Frame: Week 12
|
To compare the Week 12 histologic responder rates (≤ 6 peak eosinophils [eos]/high power field [HPF]) for APT-1011 3 mg HS with that for placebo.
HPF will be defined as a standard area of 235 square microns in a microscope with 40x lens (0.3 mm^2) and 22 mm ocular
|
Week 12
|
Mean change in number of dysphagia episodes
Time Frame: Week 0 to Week 12
|
To compare the mean change in number of dysphagia episodes from baseline to Week 12 for APT-1011 3 mg HS with that for placebo
|
Week 0 to Week 12
|
Histologic responder rates at the end of the Randomized Withdrawal Phase (RWS)
Time Frame: Week 12 to Week 52
|
To compare the histologic responder rates (≤ 6 peak eos/HPF) for APT-1011 responders randomized to continuing APT-1011 3 mg HS (maintenance) with responders randomized to placebo (withdrawal of APT-1011 3 mg HS) at the end of the RWS
|
Week 12 to Week 52
|
Percentage subjects with complete symptomatic response at the end of the RWS
Time Frame: Week 0 to Week 52
|
Percentage of subjects with complete symptomatic response (i.e., no dysphagia episodes for the 14 consecutive days prior to the end of the randomized withdrawal phase) at the end of the randomized withdrawal phase, in the RWS APT-1011 3 mg HS arm versus placebo arm
|
Week 0 to Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in EREFs from Week 0 to Week 12
Time Frame: Week 0 to Week 12
|
To compare endoscopic appearance evaluated by the mean change from baseline to Week 12 in Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) for APT-1011 3 mg HS with that for placebo.
|
Week 0 to Week 12
|
Percentage of subjects with <1 peak eos/HPF at Week 12
Time Frame: Week 12
|
To compare the percentage of subjects with <1 peak eos/HPF at Week 12 for APT-1011 3 mg HS with that for placebo.
|
Week 12
|
Mean change in PROSE Symptom Burden Score
Time Frame: Week 0 to Week 12
|
To compare the mean change from baseline to Week 12 in the day-level symptom burden utilizing the Patient Reported Outcomes Symptoms of EoE (PROSE) for APT-1011 3 mg HS with that for placebo.
|
Week 0 to Week 12
|
Mean Change in PROSE Day-Level Difficulty Swallowing
Time Frame: Week 0 to Week 12
|
To compare the mean change from baseline to Week 12 in day-level difficulty swallowing using the Patient Reported Outcomes Symptoms of EoE (PROSE) for APT-1011 3 mg HS with that for placebo.
Each symptom is rated on a numeric rating scale (NRS) with values ranging from 0 (not at all) to 10 (as bad as I can imagine).
|
Week 0 to Week 12
|
Percentage of Subjects with <15 peak eos/HPF
Time Frame: Week 12
|
To compare the percentage of subjects with <15 peak eos/HPF for APT-1011 3 mg HS with that for placebo.
|
Week 12
|
Mean Number of Dysphagia-free Days
Time Frame: Week 0 to Week 12
|
To compare the mean number of dysphagia-free days from baseline to Week 12 for APT-1011 3 mg HS with that for placebo
|
Week 0 to Week 12
|
Mean Change in Dysphagia Episodes
Time Frame: Week 0 to Week 52
|
To compare mean change in number of dysphagia episodes from baseline to the end of RWS for APT-1011 responders randomized to continue APT-1011 3 mg HS with responders randomized to placebo (withdrawal of APT-1011 3 mg HS)
|
Week 0 to Week 52
|
Mean Change in EREFs from Week 0 to Week 52
Time Frame: Week 0 to Week 52
|
To compare endoscopic appearance evaluated by the mean change from baseline to the end of RWS, in Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) for APT-1011 responders randomized to continue APT-1011 3 mg HS with responders randomized to placebo (withdrawal of APT-1011 3 mg HS).
The EREF score has a range from 0-9, with 9 being worst result.
|
Week 0 to Week 52
|
Mean Histologic Change
Time Frame: Week 0 to Week 52
|
To compare the mean change from baseline to the end of the RWS in peak eosinophil counts for APT-1011 responders randomized to APT-1011 3 mg HS with those randomized to placebo in the RWS.
|
Week 0 to Week 52
|
Mean Change in PROSE Day-Level Symptom Burden
Time Frame: Week 0 to Week 52
|
To compare the mean change in day-level symptom burden using the Patient Reported Outcomes Symptoms of EoE (PROSE) from baseline to the end of RWS, for APT-1011 responders randomized to continue APT-1011 3 mg HS with responders randomized to placebo (withdrawal of APT-1011 3 mg HS).
Day-level symptom burden has values ranging from 0 (no symptoms) to 10 (symptoms are as bad as I can imagine).
|
Week 0 to Week 52
|
Mean Change in PROSE Day-Level Difficulty Swallowing
Time Frame: Week 0 to Week 52
|
To compare the mean change in day-level difficulty swallowing using the Patient Reported Outcomes Symptoms of EoE (PROSE) from baseline to the end of randomized withdrawal phase, for APT-1011 responders randomized to continue APT-1011 3 mg HS with responders randomized to placebo (withdrawal of APT-1011 3 mg HS).
Each symptom is rated on a numeric rating scale (NRS) with values ranging from 0 (not at all) to 10 (as bad as I can imagine).
|
Week 0 to Week 52
|
Mean Change in Dysphagia-Free Days
Time Frame: Week 0 to Week 52
|
To compare the mean number of dysphagia-free days from baseline to the end of RWS, for APT-1011 responders randomized to continue APT-1011 3 mg HS with responders randomized to placebo (withdrawal of APT-1011 3 mg HS)
|
Week 0 to Week 52
|
Mean Histologic Change from Baseline to Week 12
Time Frame: Week 0 to Week 12
|
To compare mean histologic change from baseline to Week 12 for APT-1011 3 mg HS with that for placebo.
|
Week 0 to Week 12
|
Mean Change in Number of Dysphagia Episodes
Time Frame: Week 0 to Week 52
|
To compare mean change in number of dysphagia episodes from baseline at or prior to Week 52 (based on timing of > 6 peak eos/HPF) for APT-1011 responders randomized to continue APT-1011 3 mg HS with those randomized to placebo (withdrawal of APT-1011 3 mg HS)
|
Week 0 to Week 52
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Evan Dellon, MD, MPH, UNC Center for Eosphageal Diseases and Swallowing
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Hypersensitivity, Immediate
- Hypersensitivity
- Immune System Diseases
- Gastroenteritis
- Gastrointestinal Diseases
- Digestive System Diseases
- Esophagitis
- Hematologic Diseases
- Eosinophilic Esophagitis
- Eosinophilia
- Esophageal Diseases
- Peripheral Nervous System Agents
- Anti-Asthmatic Agents
- APT-1011
- Leukocyte Disorders
- Fluticasone
- Anti-Inflammatory Agents
- Bronchodilator Agents
- Autonomic Agents
- Respiratory System Agents
- Anti-Allergic Agents
Additional Relevant MeSH Terms
- Digestive System Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Hematologic Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Hypersensitivity
- Esophageal Diseases
- Leukocyte Disorders
- Eosinophilia
- Eosinophilic Esophagitis
- Esophagitis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Fluticasone
- Xhance
Other Study ID Numbers
- SP-1011-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Esophagitis
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic Esophagitis (EoE) | Eosinophilic Gastrointestinal Disorders (EGIDs)United States
-
Federico II UniversityRecruitingEsophagitis, EosinophilicItaly
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingEosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal DiseaseUnited States
-
Medical University of GrazRecruiting
-
AQILION ABCompletedEosinophilic Esophagitis (EoE)United Kingdom
-
Regeneron PharmaceuticalsSanofiActive, not recruitingEosinophilic Esophagitis (EoE)United States, Canada
-
ShireTakeda Development Center Americas, Inc.TerminatedEosinophilic Esophagitis (EoE)United States
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
-
ShireCompleted
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
Clinical Trials on APT-1011
-
Ellodi Pharmaceuticals, LPActive, not recruitingEosinophilic EsophagitisUnited States, Canada
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedGlioma | GliosarcomaUnited States
-
AutotelicbioRecruitingDiabetes Mellitus, Type 2 | Essential HypertensionKorea, Republic of
-
Boehringer IngelheimCompleted
-
Theresa PapeRecruitingPost Traumatic Stress Disorder | Mild Traumatic Brain InjuryUnited States
-
Karolinska InstitutetRegion Stockholm; Promobilia Foundation; Stroke Foundation; KID-medelCompleted
-
Qianqian QuNot yet recruitingMalignant Tumor of the Ovary | XRCC2 Gene Mutation
-
Adare Pharmaceuticals, Inc.CompletedEosinophilic EsophagitisSpain, United States, Belgium, Switzerland, Germany, Canada
-
Ikerbasque - Basque Foundation for ScienceRecruiting
-
Ellodi Pharmaceuticals, LPAvailableEosinophilic EsophagitisUnited States